ALKS Stock Alkermes plc - Complete Overview

Nasdaq / Pharmaceutical Products / Healthcare / ALKS Stock

Alkermes plc (ALKS) price per share as of 13 Jul 2018
Your sentiment
Shares Outstanding 155.04M
Avg Daily Volume 861.02K
Market Cap 7.14B
Volatility 47.34% MEDIUM


ALKS stock is a pharmaceutical products company traded on Nasdaq. It is valued at 7.14B US dollars. There are 155.04M shares outstanding which Alkermes plc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 47.34% stock on average. It brought investors a total return of -24.79% over the last 12 months. Alkermes plc stock is relatively cheap. It's P/E ratio is below the market average.



Earnings Per Share 0.00
Dividends Per Share 0.00
12 Months Price Performance Negative
Total Return Negative


3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

Roche goes for a knockout with positive triple-negative data.NewLink hanging on and providing small updates in the IDO space.Alkermes sticks the landing in schizophrenia.

Alkermes stock jumps 3% premarket after FDA approves injectable schizophrenia treatment

Alkermes Plc shares rose about 3% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved its long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. "For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides physicians with an alternative regimen to initiate patients onto any dose of ARISTADA on day one," the company said in a statement. The treatment is expected to support schizophrenia patients who have difficulties with medication complicance and continuity of care, notably for those moving from inpatient to outpatient care. "The approval of ARISTADA INITIO makes ARISTADA the first and only long-acting atypical antipsychotic that can be initiated on day one, representing an important addition to the treatment paradigm for the complex illness of schizophrenia," said David Walling, Ph.D., chief executive and principal investigator of the Collaborative Neuroscience Network. "For physicians and caregivers alike, the ARISTADA INITIO regimen provides a level of confidence that patients can walk out the door with up to two months of coverage with a proven medication in their system." About 2.4 million Americans suffer from schizophrenia, which affects men and women equally. Alkermes shares have fallen 24.8% in 2018 through Friday, while the S&P 500 has gained 1.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

Why Alkermes Tumbled 15% Today

A downgrade by a big investment bank took a toll on the company's shares today.

Why, iQiyi, and Alkermes Slumped Today

Find out which of these companies could suffer from a government move.

Lundbeck Gets An Unexpected Boon From The FDA

After years of obstinate refusal, the FDA has reversed course and granted Lundbeck permission to change the label for its depression drug Trintellix to include clinical data on cognitive benefits.The

3 Things In Biotech, April 28: Fighting Mental Disorders, And A New Strategy For Bacteria?

Achaogen secures defense funding to fight infections.Alkermes moves into the final stage of a pivotal study.Axsome divulges a promising interim readout in depression.


Name Value Action
RSI(14) 49.75 Neutral
CMO(14) -0.5062 Neutral
ADX(14) 26.56 N/A
Williams %R -8.86 Sell


ALKS Industry Sector Market
Price to Earnings 0.00 31.69 27.49 42.97
Price to Book Value 6.18 6.79 6.25 7.18
Price to Sales 7.62 3.59 3.41 4.95
Return on Equity 0.00% 11.07% 10.16% 19.24%
Return on Assets 0.00% 5.57% 4.77% 8.57%
All values TTM (trailing twelve months). Source: